Goldman Sachs Knock-Out CHKP/ DE000GG5JYX7 /
| 29/05/2024 10:44:37 | Chg.- | Bid09:39:44 | Ask09:39:44 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.75EUR | - | 1.84 Bid Size: 10,000 |
1.91 Ask Size: 10,000 |
Check Point Software... | 167.8189 USD | 31/12/2078 | Put |
GlobeNewswire
29/05
DEADLINE ALERT for LUNA, HRT, and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class ...
GlobeNewswire
29/05
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
29/05
UPDATE -- Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of L...
GlobeNewswire
29/05
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewswire
29/05
Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch
GlobeNewswire
29/05
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology...
GlobeNewswire
29/05
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KI...
GlobeNewswire
29/05
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR ...
GlobeNewswire
28/05
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire
28/05
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with...
GlobeNewswire
28/05
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
28/05
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Tril...
GlobeNewswire
28/05
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
GlobeNewswire
27/05
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...
GlobeNewswire
27/05
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
24/05
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenaden...
GlobeNewswire
23/05
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
23/05
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire
23/05
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at A...
GlobeNewswire
23/05
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire
23/05
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study i...
GlobeNewswire
23/05
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combinatio...
